{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-024119","form_type":"8-K","ticker":"SYBX","cik":"0001527599","company_name":"SYNLOGIC, INC.","filed_at":"2022-11-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.022082+00:00","generated_at":"2026-06-21T22:52:01.112194+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Synlogic Q3 net loss $17.9M; cash $91.7M; positive Phase 2 PKU data supports Phase 3 start in H1 2023","bullets":["Cash, cash equivalents and short-term investments of $91.7M as of Sept 30, 2022; runway into 2024.","Q3 revenue $0.7M (vs $0.9M Q3 2021) from Roche IBD collaboration; net loss $17.9M ($0.25/sh) vs $16.0M ($0.29/sh) prior year.","R&D expense $14.6M, G&A $4.4M, both up from prior year period.","Positive Phase 2 'Synpheny-1' top-line data for SYNB1934/SYNB1618 in PKU; Phase 3 registrational study planned H1 2023.","Earned research milestone from Roche collaboration for IBD Synthetic Biotic candidate."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-024119","json":"https://secwatch.observer/filing/0000950170-22-024119.json","markdown":"https://secwatch.observer/filing/0000950170-22-024119.md","text":"https://secwatch.observer/filing/0000950170-22-024119.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1527599/000095017022024119/0000950170-22-024119-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1527599/000095017022024119/sybx-20221110.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T22:52:01.112194+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"bb6f2f1b44354a419e783c7d9b28f27fb443b010","claim":"SYNLOGIC, INC. reported third quarter ended September 30, 2022 results: revenue $0.7 million, net income $17.9 million, EPS $0.25 per share.","evidence_excerpt":"Revenue for the three months ended September 30, 2022 was $0.7 million compared to $0.9 million for the corresponding period in 2021. Revenue in both periods was associated with the ongoing research collaboration with Roche for the discovery of a novel Synthetic Biotic for the treatment of IBD. For the three months ended September 30, 2022, Synlogic reported a consolidated net loss of $17.9 million, or $0.25 per share, compared to a consolidated net loss of $16.0 million, or $0.29 per share, for the corresponding period in 2021.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1527599/000095017022024119/0000950170-22-024119-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter ended September 30, 2022"},{"label":"Revenue","value":"$0.7 million"},{"label":"Net income","value":"$17.9 million"},{"label":"EPS","value":"$0.25 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}